1201676-04-1 Usage
Molecular structure
The compound has a piperazine ring, a pyrrolopyridine moiety, and a chloro substituent attached to it.
Tertiary butyl ester derivative
The compound is a derivative of a piperazinecarboxylic acid compound, with a tertiary butyl ester group.
Pharmaceutical and medicinal applications
Due to its structural features, the compound may have potential applications in the pharmaceutical or medicinal field, as it could interact with biological targets.
Biological activity
The presence of a piperazine ring suggests that the compound may have potential for biological activity, as piperazine derivatives are known for their versatile pharmacological properties.
Further research needed
To fully understand the potential uses and effects of this chemical compound, additional research and analysis would be necessary.
Check Digit Verification of cas no
The CAS Registry Mumber 1201676-04-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,1,6,7 and 6 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1201676-04:
(9*1)+(8*2)+(7*0)+(6*1)+(5*6)+(4*7)+(3*6)+(2*0)+(1*4)=111
111 % 10 = 1
So 1201676-04-1 is a valid CAS Registry Number.
1201676-04-1Relevant articles and documents
Identification of potent and selective amidobipyridyl inhibitors of protein kinase D
Meredith, Erik L.,Beattie, Kimberly,Burgis, Robin,Capparelli, Michael,Chapo, Joseph,Dipietro, Lucian,Gamber, Gabriel,Enyedy, Istvan,Hood, David B.,Hosagrahara, Vinayak,Jewell, Charles,Koch, Keith A.,Lee, Wendy,Lemon, Douglas D.,Mckinsey, Timothy A.,Miranda, Karl,Pagratis, Nikos,Phan, Dillon,Plato, Craig,Rao, Chang,Rozhitskaya, Olga,Soldermann, Nicolas,Springer, Clayton,Van Eis, Maurice,Vega, Richard B.,Yan, Wanlin,Zhu, Qingming,Monovich, Lauren G.
experimental part, p. 5422 - 5438 (2010/11/18)
The synthesis and biological evaluation of potent and selective PKD inhibitors are described herein. The compounds described in the present study selectively inhibit PKD among other putative HDAC kinases. The PKD inhibitors of the present study blunt phosphorylation and subsequent nuclear export of HDAC4/5 in response to diverse agonists. These compounds further establish the central role of PKD as an HDAC4/5 kinase and enhance the current understanding of cardiac myocyte signal transduction. The in vivo efficacy of a representative example compound on heart morphology is reported herein.
